{Reference Type}: Journal Article
{Title}: Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
{Author}: Abu-Rustum NR;Yashar CM;Bean S;Bradley K;Campos SM;Chon HS;Chu C;Cohn D;Crispens MA;Damast S;Dorigo O;Eifel PJ;Fisher CM;Frederick P;Gaffney DK;Han E;Huh WK;Lurain JR;Mariani A;Mutch D;Nagel C;Nekhlyudov L;Fader AN;Remmenga SW;Reynolds RK;Sisodia R;Tillmanns T;Ueda S;Wyse E;McMillian NR;Scavone J;
{Journal}: J Natl Compr Canc Netw
{Volume}: 17
{Issue}: 11
{Year}: 11 2019 1
{Factor}: 12.693
{DOI}: 10.6004/jnccn.2019.0053
{Abstract}: Gestational trophoblastic neoplasia (GTN), a subset of gestational trophoblastic disease (GTD), occurs when tumors develop in the cells that would normally form the placenta during pregnancy. The NCCN Guidelines for Gestational Trophoblastic Neoplasia provides treatment recommendations for various types of GTD including hydatidiform mole, persistent post-molar GTN, low-risk GTN, high-risk GTN, and intermediate trophoblastic tumor.